Taiwan Cell Manufacturing Co. (tcmc) debuted today at BioJapan 2026 in Yokohama (Booth C-01), showcasing Taiwan’s cell manufacturing and Cell & Gene Therapy (CGT) capabilities to global biotech and pharmaceutical professionals.
As a premier Asian biotech platform for technical collaboration and commercial partnerships, BioJapan offers tcmc a key venue to highlight its GMP, CDMO, CGT, CAR-T, and Lentiviral Vector (LV) expertise, spanning from process development to manufacturing.
On day one, tcmc’s booth drew strong international interest. Discussions centered on CGT market trends, manufacturing demands, and CDMO models, yielding valuable market insights and potential partnership opportunities.
This participation marks a strategic step for tcmc to deepen its footprint in Japan and the broader Asian market while elevating Taiwan’s profile in the CGT sector.
BioJapan 2026 runs through October 9th. tcmc invites industry professionals to visit Booth C-01 to explore collaboration opportunities.
BioJapan 2026｜PACIFICO Yokohama
tcmc｜Booth C-01
2026.10.7–10.9